Masimo's total fourth quarter revenue, including royalties, rose 6% to $112.3 million, compared to $105.6 million for the fourth quarter of 2010. Fourth quarter 2011 product revenue rose 12% to $104.7 million, compared to $93.8 million for the fourth quarter of 2010. For the fourth quarter of 2011, the company's worldwide end-user business grew 17% and represented 86% of product revenue. OEM sales, which represented the remaining 14% of product revenue, declined 12% in the fourth quarter of 2011, compared to the same period in 2010. Revenue from Masimo rainbow product sales rose 16% to $9.8 million in the fourth quarter, compared to $8.4 million for the fourth quarter of 2010.
Net income for the fourth quarter was $13.8 million, or $0.23 per diluted share, compared to reported net income of $16.1 million, or $0.26 per diluted share, in the fourth quarter of 2010. Excluding one-time expenses in the year-ago period, Masimo's adjusted net income and adjusted earnings per share for the fourth quarter of 2010 were $17.5 million and $0.29, respectively.For 2011, Masimo's total revenue rose 8% to $439.0 million, compared to $405.4 million in 2010. The company's product revenue rose 14% to $406.5 million, compared to $356.4 million in 2010. Revenue from Masimo rainbow products rose 4% to $34.1 million, compared to $32.9 million in 2010. Excluding the $4.0 million U.S. military order in 2010 that did not repeat in 2011, rainbow revenue grew by 18%. Royalty revenue declined from $49.0 million in 2010 to $32.5 million in 2011.
Masimo's net income for 2011 was $63.7 million, or $1.05 per diluted share, compared to 2010 net income of $73.5 million, or $1.21 per diluted share, which included $0.18 from the net of a one-time gain related to $30.8 million in antitrust proceeds from Covidien and offset by $14.7 million in one-time expenses. Excluding one-time items in 2010, Masimo's 2010 adjusted net income and adjusted earnings per share were $62.5 million and $1.03, respectively.
During the fourth quarter, the company shipped approximately 34,400 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, down 18% compared to approximately 41,800 in the same prior-year period. For 2011, Masimo shipped approximately 148,200 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, down 2% compared to approximately 153,200 in 2010. Masimo estimates its worldwide installed base as of December 31, 2011 to be 979,000 units, up 15% from 855,000 units as of January 1, 2011.Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, "Masimo finished 2011 with a 12% rise in fourth quarter product revenue, including 17% growth in our direct business. Strong double-digit sales growth in our U.S. acute care channel and international business, as well as a 16% increase in rainbow revenue, drove our product revenue performance in the quarter. We also grew our worldwide installed base by 15%, expanding our global reach and demonstrating the continuing demand for our superior Masimo SET pulse oximetry and rainbow SET Pulse CO-Oximetry technology."As of December 31, 2011, cash and cash equivalents were $129.9 million, compared to $88.3 million as of January 1, 2011. During the fourth quarter, the company used approximately $36 million in cash to purchase approximately 1.8 million shares of its common stock under a stock repurchase program authorized by the Board of Directors in mid-2011.
2012 Financial Guidance
Masimo expects fiscal 2012 total revenue to be approximately $483 million, including product revenue of $455 million and royalty revenue of $28 million. Included within the 2012 product revenue guidance is a rainbow revenue expectation of $45 million. The company expects fiscal 2012 GAAP earnings per share to be $1.20. Each of the components of Masimo's guidance set forth above is an estimate only and actual performance could differ.
Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. A live webcast of the conference call will be available online from the investor relations page of the company's corporate website at www.masimo.com. The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 42982286. After the live webcast, the call will be available on Masimo's website through March 14, 2012. In addition, a telephonic replay of the call will be available through February 28, 2012. The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (855) 859-2056 for international callers. Please use reservation code 42982286
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies; demand for our technologies; and expectations for total revenue, royalty revenue and product revenue, including rainbow revenue, and GAAP earnings per share, for the full fiscal year 2012. These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor Contact: Sheree AronsonMedia Contact: Dana BanksVice President, Investor Relations, Masimo CorporationManager, Public Relations, Masimo Corporation (949) 297-7043 (949) 297-7348 firstname.lastname@example.org@masimo.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.
MASIMO CORPORATION CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) December 31,January 1,20112011ASSETSCurrent assetsCash and cash equivalents
88,305Accounts receivable, net of allowance for doubtful accounts 57,01349,694Royalties receivable7,10212,000Inventories45,94445,028Prepaid expenses6,4244,535Prepaid income taxes2,9863,352Deferred tax assets11,57612,555Other current assets2,0082,136Total current assets262,935217,605Deferred cost of goods sold51,67947,184Property and equipment, net15,23915,951Intangible assets, net11,39310,497Goodwill448448Deferred tax assets16,76612,560Other assets7,6445,990Total assets
310,235LIABILITIES AND EQUITYCurrent liabilitiesAccounts payable
22,150Accrued compensation19,71721,074Accrued liabilities12,2979,832Income taxes payable570722Deferred revenue16,01916,369Current portion of capital lease obligation4850Total current liabilities75,95370,197Deferred revenue9841,554Capital lease obligation, less current portion74122Other liabilities9,4278,323Total liabilities86,43880,196EquityMasimo Corporation stockholders’ equity:Common stock5859Treasury stock(37,396)(1,209)Additional paid-in capital243,528222,206Accumulated other comprehensive income1,274925Retained earnings69,3645,664Total Masimo Corporation stockholders’ equity276,828227,645Noncontrolling interest2,8382,394Total equity279,666230,039Total liabilities and equity
310,235MASIMO CORPORATIONCONSOLIDATED STATEMENTS OF INCOME (unaudited, in thousands, except per share amounts) Three Months EndedTwelve Months EndedDecember 31,January 1,December 31,January 1,2011201120112011Revenue:Product$
356,422Royalty7,62511,79932,50148,985Total revenue112,341105,574438,988405,407Cost of goods sold38,72931,446144,854119,825Gross profit73,61274,128294,134285,582Operating expenses:Selling, general and administrative43,93044,227169,205174,089Research and development9,6198,31238,41236,000Antitrust litigation proceeds———(30,728)Total operating expenses53,54952,539207,617179,361Operating income20,06321,58986,517106,221Non-operating income (expense)(468)154141,348Income before provision for income taxes19,59521,74386,531107,569Provision for income taxes5,4295,11222,47834,164Net income including noncontrolling interests14,16616,63164,05373,405Net (income) loss attributable to the noncontrolling interests(346)(517)(353)125Net income attributable to Masimo Corporation$
73,530Net income per share attributable to Masimo Corporation stockholders:Basic$
1.21Weighted average shares used in per share calculations:Basic59,22359,14559,65958,769Diluted60,18060,83960,84560,609Cash dividend declared per share$
2.75The following table presents details of the share-based compensation expense (benefit) that is included in each functional line item in the consolidatedstatements of income above (in thousands): Three Months EndedTwelve Months EndedDecember 31,January 1,December 31,January 1,2011201120112011Cost of goods sold$
483Selling, general and administrative2,7092,51910,2689,033Research and development8367653,0252,787Total$
12,303 MASIMO CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited, in thousands) Year endedYear endedDecember 31,January 1,20112011Cash flows from operating activities:Net income including noncontrolling interests$
73,405Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:Depreciation and amortization7,3426,584Share-based compensation13,67612,303Provision for doubtful accounts231108Provision for obsolete inventory2,130619Provision for warranty costs2,5922,355Provision for deferred income taxes(3,217)(2,231)Income tax benefit from exercise of stock options granted prior to January 1, 20061,6504,851Excess tax benefit from share-based payment arrangements(67)(707)Changes in operating assets and liabilities:Increase in accounts receivable(7,549)(10,905)(Increase) decrease in royalties receivable4,898(500)Increase in inventories(3,046)(14,088)Increase in deferred cost of goods sold(4,526)(19,080)Increase in prepaid expenses(1,874)(743)(Increase) decrease in prepaid income taxes366(1,648)Increase in other assets(1,502)(1,396)Increase in accounts payable5,1595,474Increase (decrease) in accrued compensation(1,333)3,219Decrease in accrued liabilities(77)(2,281)Increase (decrease) in income taxes payable(89)940Increase (decrease) in deferred revenue(921)3,012Increase in other liabilities1,0611,729Net cash provided by operating activities78,95761,020Cash flows from investing activities:Purchase of short-term investments—(75,986)Proceeds from sale and maturities of short-term investments—132,975Purchases of property and equipment(5,057)(9,561)Increase in intangible assets(2,451)(1,937)Net cash provided by (used in) investing activities(7,508)45,491Cash flows from financing activities:Repayments on long-term debt(50)(60)Proceeds from issuance of common stock5,94310,239Excess tax benefit from share-based payment arrangements67707Dividends paid—(161,978)Repurchases of common stock(36,187)—Short swing profit recovery73—Net cash used in financing activities(30,154)(151,092)Effect of foreign currency exchange rates on cash282832Net increase (decrease) in cash and cash equivalents41,577(43,749)Cash and cash equivalents at beginning of period88,305132,054Cash and cash equivalents at end of period$
|SOURCE Masimo Corporation|
Copyright©2010 PR Newswire.
All rights reserved